Cargando…

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner

The restoration of the normal function of the tumour suppressors, such as p53, is an important strategy in tumour therapeutics. Nonsense-mediated mRNA decay (NMD) inhibition by NMD inhibitor (NMDi) upregulates functional p53 isoforms, p53β and p53γ, and activates the p53 pathway. XR-2, a novel mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ying, Wu, Meng, Zhang, Lili, Wan, Li, Li, Hexin, Zhang, Lanxin, Sun, Gaoyuan, Huang, Wei, Zhang, Junhua, Su, Fei, Tang, Min, Xiao, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525646/ https://www.ncbi.nlm.nih.gov/pubmed/36180435 http://dx.doi.org/10.1038/s41420-022-01190-3

Ejemplares similares

Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers
por: Gudikote, Jayanthi P., et al.
Publicado: (2021)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway
por: Zhanfeng, Niu, et al.
Publicado: (2016)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
por: Heldin, Angelos, et al.
Publicado: (2023)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
por: Wang, Xiaoxuan, et al.
Publicado: (2021)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()()
por: Feng, Felix Y., et al.
Publicado: (2016)

Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine
por: Palomar-Siles, Mireia, et al.
Publicado: (2022)

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53
por: Luo, Yanwei, et al.
Publicado: (2022)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression
por: Steffens Reinhardt, Luiza, et al.
Publicado: (2023)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
por: Xu, Cheng, et al.
Publicado: (2021)

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
por: Zhang, Meiqiongzi, et al.
Publicado: (2018)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

The screening of compounds regulating PD‐L1 transcriptional activity in a cell functional high‐throughput manner
por: Zhang, Lanxin, et al.
Publicado: (2023)

Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review
por: Ahmed, Syed Ijlal, et al.
Publicado: (2018)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
por: Zheng, Tongsen, et al.
Publicado: (2013)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development
por: Kazantseva, Marina, et al.
Publicado: (2018)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA
por: Niu, Guanglin, et al.
Publicado: (2021)

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
por: Xiao, Mang, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bqph038i89d8ut29bdisoo76t3